Atrial cardiomyopathy markers and new-onset atrial fibrillation risk in patients with acute myocardial infarction

• DOI: 10.1016/j.ejim.2022.04.019
• Publication Date: 2022-05-02T11:27:37Z
• Authors: Zhitong Li; Quanbo Liu; Fei Liu; Tesfaldet H. Hidru; Yiheng Yang; Shihao Wang; Lan Bai; Jing Chen; Xiaolei Yang; Yunlong Xia
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Atrial Fibrillation; Natriuretic Peptide, Brain; Myocardial Infarction; Humans; Cardiomyopathies; Biomarkers; Retrospective Studies; 3. Good health

New-onset atrial fibrillation (NOAF) after acute myocardial infarction (AMI) is common and independently correlated with poor prognosis. The purpose of this study to explore whether cardiomyopathy (ACM) markers improve NOAF risk assessment contribute therapy decision-making prognosis.We retrospectively analyzed 4713 patients AMI without a documented history (AF). We measured ACM including P-wave terminal force in ECG lead V1 (PTFV1), Left dimension (LAD), B-type natriuretic peptide (BNP). Patients were stratified into tertiles PTFV1, LAD, BNP levels. Associations between evaluated using logistic regression analysis.Overall, 222 (4.71%) had out patients. prevalence increased gradually tertiles. On multivariable analysis potential confounders, elevated significantly associated an NOAF. addition the AF factors recommended by 2020 ESC Guidelines improved discrimination for NOAF.Atrial strongly AMI. prediction performance clinical model was these markers.